ArticleEpilepsia2026
Magnetoencephalographic source imaging improves localization of the epileptogenic zone in multimodal imaging evaluation.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo assess the added diagnostic value of magnetoencephalographic source imaging (MSI) beyond conventional magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET) in localizing the epileptogenic zone, with stereo-electroencephalography (SEEG) and surgical resection serving as reference standards.
methodsAmong 101 patients prospectively enrolled with drug-resistant focal epilepsy in the EPIMAGE study to assess the diagnostic yield of non-invasive multimodal imaging (MSI, MRI, FDG-PET), those undergoing SEEG and/or surgery were analyzed to compare imaging with SEEG seizure-onset zone (SOZ) or resection zone. We employed binomial generalized linear mixed models (GLMMs) to evaluate the detection accuracy of MRI, PET, and MSI, individually and in combination, for identifying the SEEG-defined SOZ and resection zones. We further assessed the spatial concordance between imaging abnormalities and these reference standards.
resultsUsing SEEG as reference, MSI identified additional SOZ regions beyond MRI in 55.6% of patients, beyond PET in 29.6%, and beyond combined MRI + PET in 33.3%. When the resection zone served as reference, MSI added new localizing value beyond MRI in 55.6% of patients, beyond PET in 29.6%, and beyond MRI + PET in 33.3%. GLMM analysis revealed that bimodal combinations improved detection rates (MRI + PET: 73.7%; MRI + MSI: 81.3%; PET+MSI: 79.8%). The trimodal combination (MRI + PET+MSI) achieved the highest detection probability at 85.3%, significantly higher than MRI, PET, or MSI alone (p = .003, p = .008, and p = .008, respectively). MSI significantly enhanced SOZ detection when added to either MRI (p = .01) or PET (p = .05). SIGNIFICANCE: MSI adds significant localizing value to the presurgical workup of focal epilepsy by expanding the detection of the epileptogenic network beyond the limits of structural MRI and metabolic PET. The primary clinical benefit of MSI lies in its ability to identify additional seizure-onset regions in complex cases, without increasing false-positive localizations. These findings demonstrate that a multimodal approach incorporating MSI optimizes surgical planning by increasing the probability of capturing the full extent of the epileptogenic zone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.